Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242108 | 1.00 | GPR119 (0.54) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL2246047 | 1.00 | GPR119 (0.54) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL2808643 | 0.90 | USP30 (0.54) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL2808641 | 0.90 | USP30 (0.54) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL5923781 | 0.90 | RORC (0.57) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL4489075 | 0.90 | RORC (0.57) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL5923783 | 0.90 | RORC (0.57) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL4484794 | 0.90 | RORC (0.57) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL16874803 | 0.88 | PDE4B (0.46) | GPR119TACR1RORCUSP30JAK2 | |
| SCHEMBL3062563 | 0.88 | PDE4B (0.46) | GPR119TACR1RORCUSP30JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | GPR119 40/4885TACR1 2283/4885RORC 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.